The Community Resource in Targeted Therapies
Driving Knowledge. Empowering Change. Optimizing Outcomes.
ONCAlert | Upfront Therapy for mRCC
Videos  >  

Reviewing the Latest Treatment Advancements in ALL

Elias Jabbour, MD
Published Online:4:12 PM, Mon May 6, 2019


Elias Jabbour, MD, professor of medicine at The University of Texas MD Anderson Cancer Center, discusses the latest advancements in the treatment landscape for acute lymphocytic leukemia (ALL) that are moving the paradigm away from chemotherapy.

There has been a lot of evolution in this field, including the development of tyrosine kinase inhibitors (TKIs), monoclonal antibodies, bispecific T-cell engager (BiTE) antibodies, and CAR T cells, Jabbour says. For patients with Philadelphia chromosome-positive ALL, TKIs in combination with chemotherapy have shown great benefit in improving survival. Today, survival at 5 years is approaching 70%, Jabbour says.

Patients can be cured without transplantation, Jabbour says. In addition, regimens such as combination blinatumomab (Blincyto) plus ponatinib (Iclusig) are providing more chemotherapy-free options for these patients.
Copyright © TargetedOnc 2018 Intellisphere, LLC. All Rights Reserved.